Clinical Trial Update: A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication [Phase 2]

View source ↗

Summary

Phase 2 study assessing ASP4345 as add-on treatment for cognitive impairment in schizophrenia on stable doses of antipsychotic medication. The trial has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• ASP4345

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2020-10-27